Clinical trials: Sintilimab
Liver Cancer, Liver Transplant; Complications
IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation
This is a parallel assigned, open-label, perspective trial studying the safety and efficacy of intensity-modulated radiotherapy (IMRT) combined with PD-1 Blockade and Lenvatinib for Hepatocellular Carcinoma (HCC) with Vp3 Portal…
- Conditions
- Liver Cancer, Liver Transplant; Complications, Hepatocellular Carcinoma, Portal Vein Thrombosis
- Trial name
- iPLENTY-pvtt (NCT05339581)
- Testing
- intensity-modulated radiotherapy, Pembrolizumab, Sintilimab
- Where
- China
- Volunteers
- 78 people
- Sponsor
- RenJi Hospital
ICC, Metastatic Cancer
Systemic Chemotherapy Plus PD-1 for Metastasis ICC
This study were designed to verify the better method of survival for metastatic ICC. Since the traditional method for metastatic ICC was GEMOX(recommended from NCCN guideline), our previous study found better results from…
- Trial name
- NCT04398927
- Testing
- Folfirinox, Sintilimab
- Where
- China
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer, First-line Treatment
Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
This prospective, unicentric, open-labe phase I study is to evaluate the effects of autologous cytokine-induced killer cell immunotherapy combination with PD-1 inhibitor and chemotherapy in the first-line treatment of…
- Trial name
- NCT03987867
- Testing
- CIK cell, Sintilimab Injection, Pemetrexed
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreatic Neoplasms
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with sintilimab and AG in first-line therapy of patients with locally advanced or metastatic…
- Trial name
- NCT05481476
- Testing
- Surufatinib, Sintilimab, AG
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Disitamab Vedotin Combined With Sintilimab and Multimodal Radiotherapy for HER2-Positive Advanced Gastric Cancer After Second-Line Treatment Failure: A Prospective, Single-Arm Phase II Clinical Trial
Patients with HER2-positive advanced gastric cancer who experience disease progression after standard first- and second-line therapies have limited subsequent treatment options.
- Trial name
- NCT07490990
- Testing
- Disitamab vedotin + Sintilimab + Multimodality radiotherapy
- Volunteers
- 30 people
- Sponsor
- West China Hospital
CAEBV
Sintilimab and Lenalidomide as a Treatment for CAEBV
This study is a multi-center, prospective, randomized, controlled clinical study to evaluate the effectiveness of a combination regimen of Sintilimab and lenalidomide in patients with chronic active EBV infection.
- Trial name
- NCT04518982
- Testing
- Sintilimab and lenalidomide
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Zhao Wang
Locally Advanced Rectal Cancer (LARC)
To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMR
To evaluate the pathological complete response rate (pCR) of intestinal flora transplantation combined with short-course radiotherapy +CAPOX+ sintilimab in neoadjuvant therapy for locally advanced rectal cancer (pMMR/MSS type)
- Trial name
- NCT07738042
- Testing
- Sintilimab, CAPOX (oxaliplatin/capecitabine), Short-course radiotherapy
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Biliary Tract Cancer
IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
This research study is designed to establish whether the combination of IBI310 \& Sintilimab has efficacy in patients with advanced BTC
- Trial name
- NCT05653180
- Testing
- IBI310, sintilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Complete Remission Rate， CRR, Progression Free Survival
Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
This is an open-label, single-arm, multi-center Phase II clinical trial evaluating the efficacy and safety of a novel sequential regimen as first-line therapy for treatment-naïve patients with Extranodal NK/T-cell Lymphoma…
- Conditions
- Complete Remission Rate， CRR, Progression Free Survival, Overall Survival, Adverse Event
- Trial name
- SCENT-3 (NCT07542912)
- Testing
- SCA Induction followed by Response-Adapted Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Thoracic Cancer, Gynecologic Cancer
Real World Study of Four PD-1 Agents in China
Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied.
- Conditions
- Thoracic Cancer, Gynecologic Cancer, Abdomen Tumors, Malignant Melanoma
- Trial name
- NCT03966456
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Hepatocellular Carcinoma, Oligoprogression
Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment
Approximately 70% of hepatocellular carcinoma (HCC) patients are diagnosed at an advanced stage, with no opportunity for curative treatments. For these patients, systemic therapies are the main treatment modalities.
- Trial name
- NCT06592612
- Testing
- SBRT and second-line systemic therapy, Second-line systemic therapy
- Volunteers
- 70 people
- Sponsor
- Sun Yat-sen University
Soft Tissue Sarcoma
Adriamycin and Ifosfamide Combined With Sintilimab
The aim of this study was to explore the efficacy and safety of adriamycin and ifosfamide combined with sintilimab versus chemotherapy in the treatment of advanced or unresectable soft tissue sarcoma.
- Trial name
- NCT04589754
- Testing
- Sintilimab plus chemotherapy, Adriamycin-based chemotherapy
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Sun Yat-sen University
Advanced Renal Cell Carcinoma
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
The study consists of two parts, the first part is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy as…
- Trial name
- NCT05522231
- Testing
- fruquintinib+sintilimab, axitinib / everolimus, fruquintinib
- Where
- 48 sites in China
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Rectal Neoplasms
Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC
The purpose of this study is to explore whether rectal artery infusion chemotherapy combined with anti-PD1 antibody is an effective neoadjuvant therapy for the microsatellite stable locally advanced rectal cancer.
- Trial name
- RAIC (NCT05307198)
- Testing
- Oxaliplatin, Rectectomy, Capecitabine
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Gastric Cancer, Chemotherapy Effect
Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer
This is a prospective, one-arm, single-center phase II study. The objective was to evaluate the efficacy and safety of domestic PD-1 antibody Sintilimab combined with modified FLOT regimen in the treatment of metastatic gastric…
- Conditions
- Gastric Cancer, Chemotherapy Effect, Immune Checkpoint Inhibitor
- Trial name
- NCT05982301
- Testing
- Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Fudan University
Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with different tumor burden advanced-stage…
- Conditions
- Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT06632106
- Testing
- hepatic artery infusion chemotherapy, Tyrosine kinase inhibitor (TKIs), Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 97 people
- Sponsor
- First Hospital of China Medical University
Metastatic Breast Cancer
Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial
This is a multicenter, single-arm,Phase II clinical trial to explore the efficacy and safety of Eribulin combined with Sintilimab in the first-line treatment of unresectable locally advanced or metastatic HER2-negative breast…
- Trial name
- NCT06308939
- Testing
- Eribulin, Sintilimab
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Zhejiang Cancer Hospital
Advanced Solid Tumor, Cutaneous T Cell Lymphoma
A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors
This is a first in human, open-label, dose escalation and expansion Phase I study of SIM1811-03 in adult patients with advanced tumors.
- Trial name
- NCT05781386
- Testing
- SIM1811-03 or in combination with Sintilimab injectiont
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Jiangsu Simcere Biologics Co., Ltd
HCC
Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular
This study is a prospective, randomized controlled, phase II trial evaluating the efficacy and safety of neoadjuvant therapy with Sintilimab combined with SBRT in patients with resectable hepatocellular carcinoma.
- Trial name
- NCT07352007
- Testing
- SBRT, Sintilimab, Surgery
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Lei ZHAO
Sebaceous Gland Carcinoma
A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of neoadjuvant therapy with Sintilimab combined with Disitamab Vedotin in patients with locally advanced, resectable or potentially resectable sebaceous gland…
- Trial name
- NCT07740993
- Testing
- Sintilimab, disitamab vedotin
- Where
- China
- Volunteers
- 25 people
- Sponsor
- West China Hospital